EBS
Price
$8.91
Change
+$0.75 (+9.19%)
Updated
Aug 12 closing price
Capitalization
435.34M
84 days until earnings call
ELAN
Price
$17.43
Change
+$0.33 (+1.93%)
Updated
Aug 12 closing price
Capitalization
8.66B
90 days until earnings call
Interact to see
Advertisement

EBS vs ELAN

Header iconEBS vs ELAN Comparison
Open Charts EBS vs ELANBanner chart's image
Emergent Biosolutions
Price$8.91
Change+$0.75 (+9.19%)
Volume$1.95M
Capitalization435.34M
Elanco Animal Health
Price$17.43
Change+$0.33 (+1.93%)
Volume$5.88M
Capitalization8.66B
EBS vs ELAN Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. ELAN commentary
Aug 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and ELAN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 13, 2025
Stock price -- (EBS: $8.91 vs. ELAN: $17.43)
Brand notoriety: EBS: Not notable vs. ELAN: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EBS: 148% vs. ELAN: 107%
Market capitalization -- EBS: $435.34M vs. ELAN: $8.66B
EBS [@Pharmaceuticals: Generic] is valued at $435.34M. ELAN’s [@Pharmaceuticals: Generic] market capitalization is $8.66B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.38B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 0 FA rating(s) are green whileELAN’s FA Score has 0 green FA rating(s).

  • EBS’s FA Score: 0 green, 5 red.
  • ELAN’s FA Score: 0 green, 5 red.
According to our system of comparison, EBS is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 6 TA indicator(s) are bullish while ELAN’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 6 bullish, 4 bearish.
  • ELAN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than ELAN.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а +46.07% price change this week, while ELAN (@Pharmaceuticals: Generic) price change was +22.75% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.29%. For the same industry, the average monthly price growth was +12.07%, and the average quarterly price growth was +82.46%.

Reported Earning Dates

EBS is expected to report earnings on Nov 05, 2025.

ELAN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+5.29% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($8.66B) has a higher market cap than EBS($435M). ELAN has higher P/E ratio than EBS: ELAN (19.81) vs EBS (3.40). ELAN YTD gains are higher at: 43.931 vs. EBS (-6.799). ELAN has higher annual earnings (EBITDA): 1.4B vs. EBS (105M). ELAN has more cash in the bank: 487M vs. EBS (149M). EBS has less debt than ELAN: EBS (666M) vs ELAN (4.4B). ELAN has higher revenues than EBS: ELAN (4.43B) vs EBS (930M).
EBSELANEBS / ELAN
Capitalization435M8.66B5%
EBITDA105M1.4B7%
Gain YTD-6.79943.931-15%
P/E Ratio3.4019.8117%
Revenue930M4.43B21%
Total Cash149M487M31%
Total Debt666M4.4B15%
FUNDAMENTALS RATINGS
EBS vs ELAN: Fundamental Ratings
EBS
ELAN
OUTLOOK RATING
1..100
7511
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9682
PRICE GROWTH RATING
1..100
4439
P/E GROWTH RATING
1..100
4793
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew somewhat faster than ELAN’s over the last 12 months.

EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's SMR Rating (82) in the Agricultural Commodities Or Milling industry is in the same range as EBS (96) in the Biotechnology industry. This means that ELAN’s stock grew similarly to EBS’s over the last 12 months.

ELAN's Price Growth Rating (39) in the Agricultural Commodities Or Milling industry is in the same range as EBS (44) in the Biotechnology industry. This means that ELAN’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew somewhat faster than ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSELAN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
58%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
65%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
66%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 1 day ago
62%
Declines
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 13 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
63%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFNCX90.521.21
+1.35%
American Funds Fundamental Invs 529C
AGYCX18.92N/A
N/A
American Century Global Gold C
AFDRX54.43N/A
N/A
American Century Large Cap Equity R
MLOIX8.66N/A
N/A
Cohen & Steers Future of Energy I
UTMAX11.22N/A
N/A
Victory Target Managed Allocation

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with HROW. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then HROW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+9.19%
HROW - EBS
38%
Loosely correlated
+3.23%
VTRS - EBS
37%
Loosely correlated
+2.64%
AMRX - EBS
36%
Loosely correlated
+2.04%
SIGA - EBS
34%
Loosely correlated
-1.90%
ELAN - EBS
32%
Poorly correlated
+1.93%
More

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+1.93%
VTRS - ELAN
47%
Loosely correlated
+2.64%
ZTS - ELAN
47%
Loosely correlated
+0.50%
PAHC - ELAN
40%
Loosely correlated
+3.96%
SNDL - ELAN
39%
Loosely correlated
+0.50%
TLRY - ELAN
36%
Loosely correlated
+3.32%
More